Leslie, W.D. http://orcid.org/0000-0002-1056-1691
Morin, S.N.
Lix, L.M.
Martineau, P.
Bryanton, M.
McCloskey, E.V.
Johansson, H.
Harvey, N.C.
Kanis, J.A.
Article History
Received: 28 May 2019
Accepted: 21 July 2019
First Online: 2 August 2019
Compliance with ethical standards
: The study was approved by the Health Research Ethics Board for the University of Manitoba.
: Suzanne Morin: Nothing to declare for the context of this paper, but has received research grants from Amgen, Merck.Eugene McCloskey: Nothing to declare for the context of this paper, but numerous ad hoc consultancies/speaking honoraria and/or research funding from Amgen, Bayer, General Electric, GSK, Hologic, Lilly, Merck Research Labs, Novartis, Novo Nordisk, Nycomed, Ono, Pfizer, ProStrakan, Roche, Sanofi-Aventis, Servier, Tethys, UBS, and Warner Chilcott.Nicholas Harvey: Nothing to declare for the context of this paper, but has received consultancy/ lecture fees/honoraria/ grant funding from Alliance for Better Bone Health, Amgen, MSD, Eli Lilly, Servier, Shire, Consilient Healthcare, and Internis Pharma.John A. Kanis: Grants from Amgen, Lilly, Radius Health and non-financial support from Medimaps outside the submitted work.William Leslie, Patrick Martineau, Mark Bryanton, Lisa Lix, Helena Johansson: No conflicts of interest.
: The results and conclusions are those of the authors and no official endorsement by the Manitoba Centre for Health Policy, Manitoba Health, Seniors and Active Living, or other data providers is intended or should be inferred. This article has been reviewed and approved by the members of the Manitoba Bone Density Program Committee.